Amgen on Monday announced positive topline results from a Phase 3 study of a subcutaneous formulation of TEPEZZA, with 77% of patients showing a highly statistically significant proptosis response for moderate-to-severe active Thyroid Eye Disease (TED).
"The positive topline results from the Phase 3 clinical trial are an important step forward for patients and for the TEPEZZA franchise," said Jay Bradner, M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "We are pleased that the data for the subcutaneous administration of TEPEZZA via an on-body injector are consistent with the established efficacy and safety profile of TEPEZZA."
The study met its primary endpoint, showing a clinically meaningful reduction in proptosis of greater than 3 mm. Proptosis, the forward bulging of the eye, is a hallmark sign of TED. The convenience of a subcutaneous injection via an on-body injector could expand access for patients who currently receive the treatment as an intravenous infusion.
The positive data provides a significant catalyst for Amgen, potentially expanding the market for TEPEZZA, a key growth driver for the company. The convenience of a subcutaneous formulation is expected to improve patient uptake and adherence, which could lead to substantial future revenue growth and boost investor confidence in Amgen's stock (AMGN).
The successful Phase 3 trial paves the way for Amgen to submit these data to the U.S. Food and Drug Administration (FDA) for potential approval. An approval would allow Amgen to offer a differentiated product in the TED market, where TEPEZZA is already an established treatment.
Thyroid Eye Disease is a rare and serious autoimmune disease that can cause proptosis, double vision, and other debilitating symptoms. The introduction of a less invasive administration method represents a significant improvement in the standard of care for this condition.
The implications for Amgen are significant, as a subcutaneous version of TEPEZZA would solidify its leadership in the TED market and provide a new growth avenue. Investors will be closely watching for the company's planned regulatory submissions and the potential for a commercial launch.
This article is for informational purposes only and does not constitute investment advice.
